Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 11;6:e2200135. doi: 10.1200/PO.22.00135

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Efficacies and gene alterations in 74 patients treated with first-line chemotherapy containing trastuzumab for advanced HER2-positive esophagogastric and gastric cancer. AKT, protein kinase B; ATM, ataxia-telangiectasia mutated; BRAF, v-raf murine sarcoma viral oncogene homolog B; BRCA2, breast cancer susceptibility gene 2; CCND1, cyclin D1; CCNE1, cyclin E1; CN, copy number; CR, complete response; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF1R, insulin-like growth factor 1 receptor; KRAS, Kirsten rat sarcoma virus; MET, MNNG HOS transforming gene; MYC, myelocytomatosis proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PD, progressive disease; PR, partial response; PTEN, phosphatase and tensin homolog; SD, stable disease; TP53, tumor protein 53.